Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -663.0%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $21M | $22M | $15M | $9M | $48M | $108M | — | — |
| Enterprise Value | $14M | $32M | $17M | $16M | $8M | $25M | $91M | — | — |
| P/E Ratio → | -0.23 | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.16 | 1.20 | 1.43 | 1.10 | 0.58 | 2.83 | 8.24 | — | — |
| P/B Ratio | — | — | 2.71 | 36.91 | 1.93 | 1.87 | 6.36 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.85 | 1.12 | 1.12 | 0.51 | 1.50 | 6.94 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.4% | 60.4% | 60.0% | 59.9% | 62.5% | 74.6% | 79.7% | 76.0% | 71.5% |
| Operating Margin | -114.1% | -114.1% | -74.3% | -125.3% | -156.2% | -115.3% | -92.1% | -92.8% | -219.8% |
| Net Profit Margin | -121.7% | -121.7% | -74.1% | -98.4% | -148.8% | -120.2% | -92.3% | -94.4% | -222.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -663.0% | -663.0% | -266.3% | -521.2% | -157.2% | -95.6% | -172.6% | -1141.8% | -174.8% |
| ROA | -105.0% | -105.0% | -85.6% | -111.1% | -100.6% | -68.8% | -73.3% | -136.5% | -102.9% |
| ROIC | -227.3% | -227.3% | -422.2% | -582.0% | -549.2% | -929.3% | -6042.5% | -348.3% | — |
| ROCE | -228.9% | -228.9% | -162.5% | -334.3% | -151.3% | -89.1% | -150.9% | -469.6% | -137.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.19 | 4.85 | 0.50 | 0.06 | 0.08 | — | 0.14 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.60 | 0.86 | -0.23 | -0.88 | -1.00 | — | -0.12 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -1448.14 | -123.72 | -77.00 | -80.95 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.24 | 0.24 | 1.50 | 0.34 | 0.80 | 3.64 | 2.61 | 0.22 | 0.93 |
| Quick Ratio | 0.24 | 0.24 | 1.50 | 0.34 | 0.80 | 3.64 | 2.61 | 0.19 | 0.93 |
| Cash Ratio | 0.11 | 0.11 | 1.26 | 0.23 | 0.52 | 3.20 | 2.33 | 0.05 | 0.58 |
| Asset Turnover | — | 0.69 | 0.98 | 1.29 | 1.17 | 0.50 | 0.52 | 1.51 | 0.46 |
| Inventory Turnover | — | — | — | — | — | — | — | 10.37 | — |
| Days Sales Outstanding | — | 33.08 | 10.44 | 5.34 | 10.41 | 37.16 | 42.34 | 30.63 | 57.29 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.1% | 2.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.1% | 2.0% | — | — |
| Shares Outstanding | — | $10M | $5M | $1M | $920484 | $849320 | $728378 | $496427 | $461926 |
Imminent liquidity and dilution
Based on reported figures, the company trades at a P/S multiple of 0.15, which suggests that the market heavily discounts the firm's revenue potential due to persistent operating losses and the absence of a clear path to profitability in the near-term medical device landscape.
The extremely low P/S ratio relative to peers like Align Technology indicates that investors are pricing in significant execution risk rather than growth. This valuation suggests the market views the current revenue base as fragile and potentially unsustainable without further capital injections.
According to historical financial data, the company's ROIC has remained deeply negative, reaching -52.7% in 2026Q1, which indicates that the firm is currently destroying invested capital rather than compounding it through its clinical and provider-network expansion efforts.
The persistent negative returns on capital highlight a structural inability to generate sufficient margins to cover the high fixed costs of the VIP program. This trend warrants further investigation into whether the current business model can ever achieve the scale necessary to reach positive return thresholds.
As reported in recent financial statements, the asset turnover ratio has stagnated near 0.20, revealing that the company struggles to generate meaningful revenue from its existing asset base, including its growing goodwill and clinical development investments.
The low asset turnover suggests that the company's infrastructure is underutilized, likely due to the slow conversion of trained providers into active case-starters. Investors should monitor whether the company can improve its asset efficiency as it attempts to leverage its recent FDA clearances.
Based on the most recent quarterly filings, the current ratio has deteriorated to 0.27, which indicates that the company lacks the necessary liquid assets to cover its short-term obligations without relying on external financing or further equity dilution.
This liquidity position appears precarious and suggests that the firm is operating with almost no margin for error. The reliance on external capital to fund ongoing operations makes the company highly sensitive to market conditions and investor sentiment.
The most commonly misapplied metric for this business model is top-line revenue growth, which obscures the underlying cash burn and the high cost of acquiring new providers within the Vivos Integrated Provider network.
Analysts should instead prioritize the 'case start' rate per provider and the cash-to-burn ratio, as these metrics better reflect the actual clinical adoption and financial sustainability of the platform. Focusing on revenue alone ignores the potential for high customer acquisition costs to erode any value generated by new enrollments.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VVOS stock.
Vivos Therapeutics, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Vivos Therapeutics, Inc.'s return on equity (ROE) is -663.0%. The historical average is -173.3%.
Based on historical data, Vivos Therapeutics, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Vivos Therapeutics, Inc. has 60.4% gross margin and -114.1% operating margin.